Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: swisstrader who wrote (90420)	3/30/2000 7:30:00 AM
From: Manly	Read Replies (1) \| Respond to of 108040

Swiss, Glad I'm working today - hoping for rebound in market tomorrow with ERICY split announcement. That would be sweet. For those of you thinking about getting into ERICY - please don't if you plan to daytrade it, this is a longer term hold unless of course it spikes like mad prior to it's split. You never know with stocks these days. Boy, would I love a few days like up $15 or so!!!!! Glenn

To: swisstrader who wrote (90420)	3/30/2000 7:35:00 AM
From: nolimitz	Read Replies (1) \| Respond to of 108040

just when you think they've stuck the knife in as deeply as they can, expect it to go another inch or two or three.. I'm waiting for them to start twisting the damn knife to boot

To: swisstrader who wrote (90420)	3/30/2000 9:05:00 AM
From: Tassi	Read Replies (1) \| Respond to of 108040

=DJ Biotechs Down -2: 'Slightest' Momentum Moving Investors -------------------------------------------------------------------------------- 29 Mar 16:09 By Beth M. Mantz NEW YORK (Dow Jones)--Biotech investors were spooked again. The "slightest" momentum upward or downward affects investors' staying power, according to Daniel Kopp, an analyst at Madison Securities. Recently, this momentum has led to a biotechnology-wide and Nasdaq-wide selloff. This time, much of the blame is being attributed to Goldman Sachs' Abby Joseph Cohen, who reduced the recommended exposure to the stock market in the firm's allocation model Tuesday. Uncertainty arising from litigation such as the Amgen Inc. (AMGN)-Transkaryotic Therpaies Inc. (TKTX) case, or clinical trial results are sufficient to set off downspells too, analysts said. A good portion of the investors know the cycles for biotech companies and know when they are investing in profitable companies. But many of the momentum players have grabbed and dumped stocks on the mere whim that these companies are engaged in the biotechnology business, irrespective of the scientific field, product potential and financial support. The current exodus is "indiscriminate and broad-based," said Mark Augustine, an analyst at U.S. Bancorp Piper Jaffray. But if investors have done their homework, these drops shouldn't have too strong of an impact because this selling will weed out those momentum players, said Kopp. The AMEX Biotechnology Index recently fell 28.43, or 5.17%, to 521.18. Big movers include Medarex Inc. (MEDX), off 30.3% to 42 1/2. Abgenix Inc. (ABGX) fell 13.7% to 159 7/16, and Alexion Pharmaceuticals Inc. (ALXN) was down 17.7% to 69 7/8. -Beth M. Mantz; Dow Jones Newswires; 201-938-5287 (END) DOW JONES NEWS 03-29-00 04:09 PM